COMPANY RESEARCHAN2 Therapeutics, Inc.
AN2 Therapeutics is a biotechnology company focused on discovering and developing small-molecule medicines, drawing on a platform built around boron-based chemistry. Its research includes investigational treatments for infectious diseases and other conditions with significant medical need. AN2 undertakes therapeutic drug development and clinical research, distinguishing the company from businesses whose primary activity is supplying research services to others. Its official website and investor relations materials provide dated information about research priorities, drug candidates and public-company disclosures.
Company at a glance
Corporate information
- Company entity
- AN2 Therapeutics, Inc.
- Headquarters / principal office
- United States
- Founded
- Not verified
- Ownership / capital status
- Publicly tradedPublicly listed
- Official corporate reference
- https://an2therapeutics.com
- LinkedIn company page
- Independent company page not verified
Profile review: 2026-11-08 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Listed issuer and R&D focus
Nasdaq Global Select Market: ANTX
boron-based medicinal chemistry · small molecules
infectious diseases · hematology · oncology
Last independently verified:
Disease tags match recorded text mentions and require program-level verification.
Technology, programs & evidence
AN2 Therapeutics is a biotechnology company focused on discovering and developing small-molecule medicines, drawing on a platform built around boron-based chemistry. Its research includes investigational treatments for infectious diseases and other conditions with significant medical need. AN2 undertakes therapeutic drug development and clinical research, distinguishing the company from businesses whose primary activity is supplying research services to others. Its official website and investor relations materials provide dated information about research priorities, drug candidates and public-company disclosures.
Business, technology & evidence
- SecuritiesNasdaq Global Select Market: ANTX
Individual program detail is not recorded. Consult the original sources below.
Related news & literature
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
Showing 0 / 0 related items
No cataloged update explicitly mentions this company.
Same-field reading (not company-specific)
Research this company together
Discussions are for signed-in members. Personal notes remain separate from company research.
Sign in to joinSources & open questions
- Official issuer and R&D disclosure · AN2 Therapeutics, Inc. ↗AN2 Therapeutics, Inc. ·
- Official issuer and R&D disclosure · AN2 Therapeutics, Inc. ↗AN2 Therapeutics, Inc. ·
- Official issuer and R&D disclosure · AN2 Therapeutics, Inc. ↗AN2 Therapeutics, Inc. ·
Inclusion is not endorsement or partner qualification. Assess company claims, clinical evidence, and project-specific capabilities separately.